Maria Sundvall
MD PhD; Specialist Physician in Clinical Oncology
mahesu@utu.fi Kiinamyllynkatu 10 Turku |
Asiantuntijuusalueet
clinical oncology; breast and prostate cancer; targeted cancer therapeutics; cancer biology; cell signaling; posttranslational modifications; dna repair pathways
clinical oncology; breast and prostate cancer; targeted cancer therapeutics; cancer biology; cell signaling; posttranslational modifications; dna repair pathways
Biografia
Maria Sundvall received her MD degree from the University of Turku in 2003, and defended her PhD thesis at the Department of Medical Biochemistry and Genetics, University of Turku, in 2007. From 2011 she worked nearly 4 years as a postdoctoral fellow in the laboratory of Prof. Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. After returning to Finland in 2015 she established her own research group at the University of Turku. Dr. Sundvall received a specialist physician degree in clinical oncology in 2018. Since 2018 Dr. Sundvall has worked as a part-time clinical lecturer at the Institute of Biomedicine, a part-time Academy of Finland clinical researcher and a part-time specialist physician in clinical oncology at Turku University Hospital.
Maria Sundvall received her MD degree from the University of Turku in 2003, and defended her PhD thesis at the Department of Medical Biochemistry and Genetics, University of Turku, in 2007. From 2011 she worked nearly 4 years as a postdoctoral fellow in the laboratory of Prof. Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. After returning to Finland in 2015 she established her own research group at the University of Turku. Dr. Sundvall received a specialist physician degree in clinical oncology in 2018. Since 2018 Dr. Sundvall has worked as a part-time clinical lecturer at the Institute of Biomedicine, a part-time Academy of Finland clinical researcher and a part-time specialist physician in clinical oncology at Turku University Hospital.
Tutkimus
Dr. Sundvall has 20 years of experience in studying molecular mechanisms of cancer. Currently she is a principal investigator at University of Turku, and her group is focusing on investigating the role fo DNA repair pathways in prostate cancer. Links:
https://www.utu.fi/en/university/faculty-of-medicine/institute-of-biomedicine/research/cancer-research
Opetus
Dr. Sundvall has several years of experience in teaching medical students as a clinical lecturer and a university teacher in the fields of medical biochemistry, molecular medicine and cancer during the last 15 years.
Dr. Sundvall has several years of experience in teaching medical students as a clinical lecturer and a university teacher in the fields of medical biochemistry, molecular medicine and cancer during the last 15 years.
Julkaisut
- High comorbidity and tumor proliferation predict survival of localized breast cancer patients after curative surgery: A retrospective analysis of real-world data in Finland (2025)
- Surgical Oncology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Phage Biosensor for the Classification of Metastatic Urological Cancers from Urine (2024)
- Life
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Syövän kohdennettujen lääkehoitojen tulevaisuus (2024)
- Duodecim
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - TIMP-1 is an activator of MHC-I expression in myeloid dendritic cells with implications for tumor immunogenicity (2024)
- Genes and Immunity
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - xCT as a Predictor for Survival in a Population‐Based Cohort of Head and Neck Squamous Cell Carcinoma (2024)
- Cancer Medicine
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Effect of caldesmon mutations in the development of zebrafish embryos (2023)
- Biochemical and Biophysical Research Communications
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Glucocorticoid receptor-induced non-muscle caldesmon regulates metastasis in castration-resistant prostate cancer (2023)
- Oncogenesis
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study (2023)
- Cancer Medicine
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - TSPO is a potential independent prognostic factor associated with cellular respiration and p16 in head and neck squamous cell carcinoma (2023)
- Frontiers in Oncology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Ex vivo -mallit ja nestebiopsia yksilöllistetyssä syövänhoidossa (2021)
- Duodecim
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - Geeniohjatun syövän hoidon työryhmä hoitopäätösten apuna : Läntisen syöpäkeskuksen kokemus (2021)
- Duodecim
(D1 Artikkeli ammattilehdessä) - More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond (2021)
- Cancers
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - Therapeutic Potential of Targeting the SUMO Pathway in Cancer (2021)
- Cancers
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - Role of Ubiquitin and SUMO in Intracellular Trafficking (2020)
- Current Issues in Molecular Biology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Uusia työkaluja paikallisesti edenneen ja etäpesäkkeisen eturauhassyövän lääkehoitoon (2020)
- Duodecim
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - PARP Inhibitors in Prostate Cancer-the Preclinical Rationale and Current Clinical Development (2019)
- Genes
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - Role of Ubiquitin and SUMO in Intracellular Trafficking (2019) SUMOylation and Ubiquitination: Current and Emerging Concepts Maria Sundvall
(O2 Muu julkaisu ) - Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin (2018)
- Scientific Reports
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - SUMOylation regulates nuclear accumulation and signaling activity of the soluble intracellular domain of the ErbB4 receptor tyrosine kinase (2017)
- Journal of Biological Chemistry
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - ERBB4 Promoter Polymorphism Is Associated with Poor Distant Disease-Free Survival in High-Risk Early Breast Cancer (2014)
- PLoS ONE
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )